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Abstract
Objective—To evaluate the safety of combination antiretroviral therapy (ART) in conception and 
pregnancy in different health systems.
Design—A pilot ART registry to measure the prevalence of birth defects and adverse pregnancy 
outcomes in South Africa and Zambia.
Methods—HIV-infected pregnant women on ART prior to conception were enrolled until 
delivery, and their infants were followed until 1 year old.
Results—Between October 2010 and April 2011, 600 women were enrolled. The median CD4+ 
cell count at study enrollment was lower in South Africa than Zambia (320 vs. 430 cells/μl; P < 
0.01). The most common antiretroviral drugs at the time of conception included stavudine, 
lamivudine, and nevirapine. There were 16 abortions (2.7%), one ectopic pregnancy (0.2%), 12 
(2.0%) stillbirths, and 571 (95.2%) live infants. Deliveries were more often preterm (29.7 vs. 
18.4%; P = 0.01) and the infants had lower birth weights (2900 vs. 2995 g; P = 0.11) in Zambia 
compared to South Africa. Thirty-six infants had birth defects: 13 major and 23 minor. There were 
more major anomalies detected in South Africa and more minor ones in Zambia. No neonatal 
deaths were attributed to congenital birth defects.
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Conclusions—An Africa-specific, multi-site antiretroviral drug safety registry for pregnant 
women is feasible. Different prevalence for preterm delivery, delivery mode, and birth defect types 
between women on preconception ART in South Africa and Zambia highlight the potential impact 
of health systems on pregnancy outcomes. As countries establish ART drug safety registries, 
documenting health facility limitations may be as essential as the specific ART details.
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Introduction
With the widespread availability of affordable combination antiretroviral therapy (ART) in 
sub-Saharan Africa, HIV-infected womenare living longer and becoming pregnant while on 
ART [1–3]. Furthermore, women in developing countries are often exposed to multiple risk 
factors for adverse pregnancy outcomes, such as poor nutrition, anemia, and untreated 
hypertension [4–6]. Whereas individual-level variables areoften considered in ART drug 
safety studies, very few analyses look at the influence of health systems on pregnancy 
outcomes in women on ART [7,8]. Population-level characteristics, clinical guidelines and 
policies, and health systems vary within sub-Saharan Africa and may impact the detection 
and occurrence of adverse maternal, fetal, and newborn outcomes.
Data regarding antenatal ART and risk of stillbirths, preterm delivery (PTD), and other 
adverse outcomes are mixed. A district-wide Zambian obstetric database comprised 
approximately 70% of delivery data from primary urban health centers and 30% from the 
tertiary hospital, and found that antenatal ART compared to none led to decreased odds of 
stillbirth [9]. However, a study in Botswana based in six government hospitals, two of which 
were tertiary referral centers, demonstrated an increased risk of PTD, small for gestational 
age (SGA), and stillbirth in women on prepregnancy ART [10]. The difference in findings 
may be due to the possible increased proportion of complicated pregnancies in the hospital-
based population and higher skilled health care workers’ ability to document clinical details. 
Different settings may be an unaccounted variable in analyses looking at ART exposure and 
pregnancy outcomes.
The WHO recommends establishing pregnancy registries for ART surveillance when 
feasible [11]. The diverse structure of health systems found in developing countries may 
affect the implementation of such registries and the ability to detect adverse outcomes, 
especially congenital anomalies. The scope of technology, human resources, and clinical 
expertise needs to be considered. The Maternal Events and Pregnancy Outcomes in a Cohort 
of HIV-Infected Women Receiving ART in sub-Saharan Africa (MEP) study measured the 
congenital anomalies and pregnancy outcomes reported in women receiving ART at 
conception and during pregnancy through a pilot program in two unique health systems. 
Sharing the baseline population characteristics and study outcomes between our distinct 
settings may inform patients, health care workers, and policy-makers on the limitations and 
strengths of drug safety monitoring in sub-Saharan Africa.
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Similar to a multi-country drug registry, the study was conducted in two different health 
systems: referral hospitals with specialists (South Africa) and primary health facilities with 
midwives (Zambia). South Africa and Zambia rank among the top 10 countries worldwide 
affected by the HIV epidemic [12].
In South Africa, study activities from enrollment to exit took place at the Dr George 
Mukhari Hospital (DGMH), a tertiary hospital affiliated with the University of Limpopo, 
which is located north of Pretoria. It conducts over 10 000 deliveries per year, composed of 
routine obstetrics from nearby communities and high-risk patients in the region [13]. Due to 
low numbers of enrollment, additional recruitment occurred at two affiliated primary health 
centers with obstetric and HIV services. In Zambia, five primary health centers in the capital 
city of Lusaka were selected; these sites are part of a larger public-sector network that 
conducts approximately 60 000 total deliveries annually [14]. Chosen for their high patient 
volume, the Zambian sites provide low-risk obstetric and HIV services to approximately 20 
000 pregnant women annually. Most pregnant women in the public sector receive their 
antenatal care from nurse-midwives at primary health centers; HIV infection is not a reason 
for hospital referral. There is no capacity to perform cesarean deliveries or provide advanced 
clinical care for mother or newborn at these centers.
Study procedures
Inclusion criteria were HIV-infected pregnant women on combination ART at conception 
and age at least 18 years. Exclusion criteria included a history of mental illness; any 
condition that would make participation in the study unsafe; and inability to provide 
informed consent. Maternal participants were recruited from the antenatal or HIV care 
clinic. Women were followed prospectively until delivery and their infants until 1 year old.
Maternal study visits were scheduled on the same day as antenatal care visits. Gestational 
age at enrollment was determined by the last menstrual period in Zambia, whereas in South 
Africa, most participants underwent a dating ultrasound. Laboratory values, HIV test date, 
and ART regimens were extracted from the antenatal card or clinical file. There were no 
study-specific laboratory tests and clinical studies beyond routine care in either health 
system. Details regarding hospitalizations and deaths were recorded by verbal report and/or 
medical chart extraction. Autopsies for infant participants were offered in South Africa only.
The infants born in the study were enrolled at birth or soon after. For multiple gestations, 
both infants were enrolled. Infant participants underwent a physical examination at every 
study visit (birth, 6 weeks, 3 months, 6 months and 1 year old).
In South Africa, the participants were examined by specialists and infants with suspected 
congenital anomalies by the clinical geneticist. The specialists also provided routine clinical 
care to participants. In Zambia, the study-specific midwives were specially trained on 
physical examinations to look for congenital anomalies.
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In-country specialists and the South African geneticist (via electronic consultation) were 
available upon request.
The study team telephoned participants who missed visits. If a participant failed to return, at 
least one home visit was conducted. Lost to follow-up was originally defined as no contact 
for 6 months from the last study visit and was revised to 6 months from the date of study 
restart when the study was briefly suspended due to changes in funding mechanisms. Data 
were included in the analysis from participants who re-enrolled on their own accord even 
though they were absent for 6 or more months.
Data analysis
The outcomes of interest included abortion, stillbirth, PTD, neonatal death, and congenital 
anomalies. ‘Abortion’ was defined as a pregnancy loss at less than 28 weeks gestation and 
birth weight below 1000 g [15]. The only exception was an infant less than 28 weeks’ 
gestation and who weighed 900 g, but was classified as a live birth to match the twin, who 
weighed 1000 g. ‘Stillbirth’ was a fetal death occurring prior to delivery of at least 28 
weeks’ gestation or at a birth weight of at least 1000 g. ‘Term’ referred to deliveries of at 
least 37 weeks’ gestation, whereas ‘preterm’ comprised viable deliveries of less than 37 
weeks’ gestation. ‘Neonatal deaths’ occurred within the first 28 days of life.
Physical examinations were performed at infant study visits to identify ‘congenital 
anomalies’. Minor and major birth defects were reviewed and classified by the clinical 
geneticist. A major congenital anomaly has an adverse outcome on either the function or the 
social acceptability of the individual, and a minor congenital anomaly has no medical or 
cosmetic importance [16]. When a live or stillbirth infant had more than one anomaly, he/she 
was categorized by the anomaly with higher severity.
Analyses were conducted via SAS version 9.2 (SAS Institute, Cary, North Carolina, USA). 
Maternal characteristics and pregnancy and infant outcomes were analyzed for differences 
between countries via Pearson chi-square test, Fisher’s exact test, and Wilcoxon rank-sum 
test.
The study was approved by the ethical review committees at the Harvard School of Public 
Health (Boston, Massachusetts, USA), Medical University of Southern Africa (Pretoria, 
South Africa), University of Zambia (Lusaka, Zambia), University of Alabama at 
Birmingham (Birmingham, Alabama, USA), and University of North Carolina at Chapel 
Hill (Chapel Hill, North Carolina, USA).
Results
From October 2010 to April 2011, 697 women were recruited and 636 were screened. Of the 
600 women who were enrolled (300 in South Africa, 300 in Zambia), three were never 
pregnant and one had initiated ART after conception. Whereas one woman withdrew prior to 
delivery, seven (one in South Africa, six in Zambia) participants were lost to follow-up. Due 
to twin gestations, 588 women contributed 600 pregnancy outcomes (Fig. 1).
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The mean number of study visits, including enrollment and exit, was 3.4 (SD 1.6) in South 
Africa and 2.4 (SD 1.3) in Zambia. There was one postnatal maternal death in Zambia due to 
severe anemia following home delivery, complicated by bleeding. The last infants exited the 
study in October 2012 in Zambia and in December 2012 in South Africa.
Characteristics of the study population
Maternal characteristics at enrollment are shown in Table 1. More participants in Zambia 
compared to South Africa were married (87.9 vs. 19.4%; P < 0.0001), whereas more in 
South Africa compared to Zambia enrolled into the study in the first trimester (11.7 vs. 
6.4%; P = 0.017). The median parity in Zambia was higher than those in South Africa (three 
vs. two; P < 0.0001). More participants in Zambia had syphilis (6.4 vs. 1.0%; P < 0.0001), 
whereas more in South Africa had anemia (27.4 vs. 10.8%; P < 0.0001). Overall, two (0.3%) 
maternal participants reported having a previous pregnancy with an anomaly, and 73 
(12.2%) women had one or more prior PTD with a median gestational age of 29.5 weeks 
[interquartile range (IQR) 28–32]. All 31 (5.2%) women who reported recreational drug use 
during the index pregnancy were in Zambia, of whom 30 drank alcohol (P < 0.0001).
Maternal participants in Zambia were diagnosed with HIV earlier (35.6 vs. 29.3 months; P = 
0.010) and had been on triple-drug ART longer (27.4=vs. 17.2 months; P < 0.0001) than 
those in South Africa. Almost all participants were WHO stage 1 or 2 at study enrollment. 
The median CD4+ cell count at study enrollment was lower in South Africa than Zambia 
(320 vs. 430 cells/μl; P < 0.0001).1
The most common antiretroviral drugs at the time of conception included stavudine (d4T), 
lamivudine (3TC), and nevirapine (NVP). Exposure to d4T was higher in South Africa than 
Zambia (55.9 vs. 30.3%; P < 0.0001), whereas tenofovir (TDF) use in Zambia was almost 
double that in South Africa (44.1 vs. 24.7%; P < 0.0001). More women in South Africa 
compared to Zambia were exposed to efavirenz (EFV) (52.5 vs. 25.6%; P < 0.0001) or 
protease inhibitor (8.4vs. 1.7%; P = 0.0002), but protease inhibitor use was uncommon 
overall.
Pregnancy outcomes and congenital anomalies
Pregnancy outcomes are shown in Table 2. There were 17 (2.9%) nonviable pregnancies: 16 
abortions (six in South Africa, 10 in Zambia) and one ectopic pregnancy. Of the 12 
stillbirths, 75% were preterm and 25% were term. There were more preterm births in 
Zambia than in South Africa (29.7 vs. 18.4%; P = 0.010). More infants were born by 
cesarean delivery in South Africa than in Zambia (18.2 vs. 7.0%; P < 0.0001). Infants in 
Zambia compared to South Africa had lower mean birth weight (2900 vs. 2995 g; P = 0.106) 
and shorter mean lengths (48 vs. 50 cm; P < 0.0001). In addition, there were seven neonatal 
deaths in Zambia and one in South Africa (P = 0.079).
We identified 38 congenital anomalies in 36 individual infants (Fig. 2). One infant with 
multiple anomalies had a major birth defect, whereas the other had two minor birth defects. 
1At the time of the study, maternal HIV RNA PCR was not measured as part of standard of care for HIV care and treatment during 
pregnancy in either country.
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Thus, 23 infants had minor anomalies and 13 had major anomalies, giving a major 
congenital anomaly prevalence of 2.2% among women who conceived on combination ART. 
The most common congenital anomalies were minor – umbilical hernia and polydactyly – 
affecting 18 infants. More major than minor congenital anomalies were detected in South 
Africa, whereas in Zambia, more minor than major congenital anomalies were detected. One 
stillbirth had a major anomaly, ambiguous genitalia; no neonatal deaths were attributed to 
congenital birth defects.
Indications for nonelective cesarean deliveries are shown in Table 3. Fetal distress, poor 
progress of labor, and severe preeclampsia remote from delivery were the most common 
indications.
Discussion
Pregnancy outcomes differed significantly between our prospective cohorts of women who 
conceived on combination ART in South Africa and Zambia: PTD, low birth weight (LBW) 
infants, mode of delivery, major and minor congenital anomalies, and neonatal deaths. Some 
baseline characteristics varied significantly between the countries, highlighting the diversity 
of the HIV-infected pregnant population and resource availability in sub-Saharan Africa. 
Whereas the higher risk of PTD in Zambia may be attributable to differences in maternal 
characteristics, such as higher parity [17], higher prevalence of syphilis [18], and higher rate 
of alcohol use [19], the disparity between the settings may also contribute. Syphilis and 
hemoglobin screening were often not done in Zambia. On the contrary, participants in South 
Africa received hospital-based antenatal care from an obstetrician and were more likely to 
undergo routine antenatal testing. Screening may have led to treatment of infections and 
consequently less incidence of PTD compared to Zambia. In addition, the non-significant 
mean birth weight difference of 95 g between the two countries may demonstrate the 
beneficial accuracy of gestational age ascertainment by ultrasound or clinical estimate over 
using last menstrual period [20]. The addition of dating ultrasounds in Zambian participants 
may have mitigated the PTD incidence [21].
The strengths of our study are numerous. The lost to follow-up rate was only 1.2% prior to 
delivery with an overall 2.0% of participants excluded in the analysis. Study sites spanned 
two countries in sub-Saharan Africa at different levels of the health system. Participants 
were recruited from government clinics, reflecting common drug exposures [22]. In 
addition, the study procedure to detect congenital anomalies was a simple, nonlabor-
intensive physical examination of the infant. With adequate training and mentorship, the 
midwives performed infant examinations and confirmed findings with specialists as needed. 
Finally, our cohort continued preconception ART throughout pregnancy, representing a 
group we expect to encounter commonly in the future as combination ART eligibility 
criteria broaden worldwide [11].
The higher rate of cesarean deliveries (with higher proportion of elective indications), higher 
detection of major congenital anomalies, and lower incidence of neonatal deaths likely 
reflect bolstered clinical resources in South Africa compared to those in Zambia. Lack of 
appropriate-sized endotracheal tubes, limited incubators, and inability to diagnose 
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definitively the major causes of neonatal deaths result in a poor survival rate for newborns 
admitted to the neonatal ICU in Zambia. A study in the United States showed significantly 
fewer in-hospital deaths among infants delivered at a hospital with a high-level neonatal ICU 
(NICU) than other hospitals [23]. Moreover, the study participants in South Africa were 
evaluated by a pediatrician and clinical geneticist as needed. The national incidences of 
neonatal encephalopathy and neonatal deaths decrease with increased access to skilled care 
at delivery [24]. As drug safety studies look at the risk of PTD, LBW, congenital anomalies, 
and perinatal mortality with ART exposure at conception and during pregnancy, aspects of 
health systems should be considered.
The significantly lower gestational age at study enrollment, utilization of autopsies, and 
higher participant retention in the study likely signify either better health-seeking behavior 
or more developed health care infrastructure or both in South Africa compared to Zambia. 
Two or more antenatal care visits compared to fewer has been associated with decreased risk 
of stillbirth [25]. However, because participants generally enrolled in the study in the late 
second trimester, first-trimester abortions and second-trimester losses are likely 
underrepresented in this cohort of HIV-infected pregnant women on pre-conception ART. 
The Development of Antiretroviral Therapy in Africa (DART) trial in Zimbabwe found 
21.5% of outcomes were spontaneous abortions and intrauterine deaths less than 22 weeks’ 
gestation [26], whereas nonelective abortions comprised of 36.6% of pregnancy outcomes in 
the Tshepo study [27].
With regard to HIV care and treatment, women in Zambia initiated ART for longer durations 
before the index pregnancy and had higher CD4+ cell counts than women in South Africa. In 
addition, antiretroviral drug exposure between the two countries was significantly different, 
with many women in Zambia being exposed to TDF and NVP, whereas d4T and EFV were 
commonly used in South Africa. In 2010, the Zambian national guidelines recommended 
d4T for use in second-line regimens only due to its toxicity profile and CD4+ cell count 
threshold of 350 cells/μl for ART eligibility in pregnant women [28]. The difference in 
national policy and guidelines may result in higher numbers of ART-exposed pregnancies in 
Zambia compared to South Africa among healthier HIV-infected women who are willing to 
initiate treatment. The capacity to provide broader combination ART coverage to the HIV-
infected population may imply stronger support for HIV care and treatment programs in 
Zambia than South Africa. Such inequalities within health systems may also impact 
associations among specific ART exposures and pregnancy outcomes.
Study limitations
Several limitations are acknowledged. First, most participants enrolled in the study after 20 
weeks’ gestation, a common time for pregnant women to book antenatal care [14]; so 
abortions were likely underrepresented. Second, we might have missed nonviable anomalies 
as autopsies for any deaths, including abortions and stillbirths, werenot offered as part of the 
study in Zambia and not uniformly accepted in South Africa. Third, because we did not add 
resources beyond the local standards of care, there is heterogeneity in estimated gestational 
age (EGA). Finally, we did not validate infant examinations by midwives for proficiency to 
detect congenital anomalies, and so birth defects may be underestimated in Zambia. The 
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study team in Zambia, though, did detect a number of congenital anomalies, demonstrating 
promise that such skills can be transferred to nonspecialists.
In conclusion, pharmacovigilance of combination ART prior to conception and during the 
antenatal period is a critical undertaking in sub-Saharan Africa where the burden of disease 
is high [2]. The potential impact of health systems on the detection of congenital anomalies 
and incidences of stillbirths, preterm deliveries, and neonatal deaths highlights the 
importance of comparing facility-level, as well as individual-level variables. Patients should 
be encouraged to establish antenatal care early to lessen the risk of adverse pregnancy 
outcomes, if any, with ART exposure. Health care workers should be trained in newborn 
examination and low-technology measures to not only detect congenital anomalies, but also 
diminish the incidences of perinatal mortality. Standard definitions and high-quality data 
collection are currently lacking in resource-limited settings [29]. Policy-makers should strive 
to incorporate health system measurements in monitoring and evaluation, especially as 
investments improve clinical standards of care. International sentinel sites for ART 
surveillance may be a preferred alternative to routine registries in developing countries. 
Sentinel sites should be equipped with a minimum package of resources to ascertain 
outcomes accurately, such as PTD. Ultrasound studies to determine EGA would require the 
ultrasound machine, continuous supplies, and a trained health care worker with months of 
mentorship [30]. Although gestational age estimation would improve, health care costs in 
resource-limited settings would rise with unlikely reduction of adverse pregnancy outcomes 
[31]. Findings from sentinel sites may then not be generalizable to the wider HIV-infected 
pregnant population. As countries establish ART drug safety registries, documenting the 
limitations of health facility levels, including technology and human resources, may be as 
essential as the specific ART drug regimen and length of exposure.
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Fig. 1. Flow diagram of maternal participant recruitment, enrollment, and retention and 
pregnancy outcomes
Maternal Events and Pregnancy Outcomes Study, 2010–2012.
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Fig. 2. Congenital anomalies in infant participants by major and minor categories in a cohort of 
HIV-infected women on combination antiretroviral therapy at the time of conception by country
Maternal Events and Pregnancy Outcomes Study, 2010–2012 (N = 36).
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Table 1
Characteristics of maternal participants at study enrollment and/or during pregnancy in a cohort of HIV-
infected women on combination antiretroviral therapy at the time of conception by country.
Characteristic
Overall
[N = 596 (%)]
South Africa
[N = 299 (%)]
Zambia
[N = 297 (%)] P value
Marital status
 Single or never married  253 (42.4)  239 (79.9)    14 (4.7) <0.0001
 Married or cohabitinga  319 (53.5)    58 (19.4)  261 (87.9)
 Divorced, separated, or widowed    24 (4.0)      2 (0.7)    22 (7.4)
Education (highest level completed)
 None    67 (11.2)    32 (10.7)    35 (11.8)   0.087
 Primary  306 (51.3)  169 (56.5)  137 (46.1)
 Secondary  192 (32.2)    83 (27.8)  109 (36.7)
 Tertiary    30 (5.0)    14 (4.7)    16 (5.4)
 Missing      1 (0.2)      1 (0.3)      0 (0)
Age at study enrollment, median years (IQR)    31 (28, 35)    31 (28, 35)    31 (28, 35)   0.854**
 <20      3 (0.5)      0 (0)      3 (1.0)   0.038*
 20–24    49 (8.2)    17 (5.7)    32 (10.8)
 25–29  158 (26.5)    88 (29.4)    70 (23.6)
 30–34  223 (37.4)  115 (38.5)  108 (36.4)
 ≥35  163 (27.3)    79 (26.4)    84 (28.3)
Gestational age at study enrollment, median weeks (IQR)    24 (18, 31)    25 (17, 31)    24 (19, 31)
 ≤12 weeks gestation    54 (9.1)    35 (11.7)    19 (6.4)   0.017
 13–26 weeks gestation  294 (49.3)  133 (44.5)  161 (54.2)
 >26 weeks gestation  248 (41.6)  131 (43.8)  117 (39.4)
Gravidity, median      3 (2, 4)      3 (2, 4)      4 (3, 5)
 1    34 (5.7)    22 (7.4)    12 (4.0) <0.0001
 2–3  313 (52.5)  188 (62.8)  125 (42.1)
 4–5  200 (33.6)    78 (26.1)  122 (41.1)
 ≥6    49 (8.2)    11 (3.7)    38 (12.8)
Parity, median      2 (1, 3)      2 (1, 3)      3 (2, 4)
 0    45 (7.6)    27 (9.0)    18 (6.1) <0.0001
 1–2  324 (54.4)  197 (65.9)  127 (42.8)
 3–4  185 (31.0)    68 (22.7)  117 (39.4)
 ≥5    42 (7.0)      7 (2.3)    35 (11.8)
Syphilis status during this pregnancy
 Nonreactive  467 (78.4)  285 (95.3)  182 (61.3) <0.0001
 Reactive    22 (3.7)      3 (1.0)    19 (6.4)
 Not done  107 (18.0)    11 (3.7)    96 (32.3)
Hemoglobin during this pregnancy, median mg/dl (IQR) 11.3 (10.4, 12.1) 11.2 (10.3, 12.1) 11.6 (10.4, 12.1)   0.216**
 ≥11  167 (28.0)  107 (35.8)    60 (20.2) <0.0001*
 7–10.9  113 (19.0)    81 (27.1)    32 (10.8)
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Characteristic
Overall
[N = 596 (%)]
South Africa
[N = 299 (%)]
Zambia
[N = 297 (%)] P value
 <7      1 (0.2)      1 (0.3)      0 (0)
 Not done  315 (52.9)  110 (36.8)  205 (69.0)
History of congenital anomaly
 No  591 (99.2)  298 (99.7)  293 (98.7)   0.341*
 Yes, one prior pregnancy with congenital anomaly      2 (0.3)      0 (0)      2 (0.7)
 Unknown      3 (0.5)      1 (0.3)      2 (0.7)
History of preterm delivery
 No  523 (87.8)  262 (87.6)  261 (87.9)   0.0842
 Yes, one previous preterm delivery    61 (10.2)    30 (10.0)    31 (10.4)
 Yes, >1 previous preterm delivery    12 (2.0)      7 (2.3)      5 (1.7)
Gestational age of last preterm delivery if applicable, median weeks 
(IQR)
29.5 (28, 32)    29 (26, 32)    30 (28, 32)   0.417**
Recreational drug use (including illegal substances) during this 
pregnancy
 No  565 (94.8)  299 (100.0)  266 (89.6) <0.0001
 Yes, alcohol    30 (5.0)      0 (0)    30 (10.1)
 Yes, traditional or herbal medicine      1 (0.2)      0 (0)      1 (0.3)
HIV infection diagnosis, months (IQR) (timing prior to conceptionb) 32.0 (16.4, 52.4) 29.3 (13.3, 52.0) 35.6 (18.6, 53.3)   0.010**
 <6 months    49 (8.2)    38 (12.7)    11 (3.7)   0.002
 6–12 months    55 (9.2)    31 (10.4)    24 (8.1)
 12–23 months  117 (19.6)    49 (16.4)    68 (22.9)
 2–4 years  192 (32.2)    93 (31.1)    99 (33.3)
 5–10 years  179 (30.0)    86 (28.8)    93 (31.3)
 >10 years      4 (0.7)      2 (0.7)      2 (0.7)
HAART start date, months (IQR) (timing prior to conceptionb) 22.0 (10.2, 39.3) 17.2 (7.5, 32.5) 27.4 (14.9, 45.3) <0.0001**
 <6 months    81 (13.6)    59 (19.7)    22 (7.4) <0.0001
 6–12 months    91 (15.3)    61 (20.4)    30 (10.1)
 12–23 months  141 (23.7)    63 (21.1)    78 (26.3)
 2–4 years  175 (29.4)    74 (24.7)  101 (34.0)
 5–10 years  108 (18.1)    42 (14.0)    66 (22.2)
WHO stage at enrollment
 Stage 1 or 2  590 (99.0)  297 (99.3)  293 (98.7)   0.407
 Stage 3 or 4      6 (1.0)      2 (0.7)      4 (1.3)
Last CD4+ cell count prior to enrollment, median cells/μl (IQR)  385 (254, 519)  320 (205, 465)  430 (296, 604)
 0–199    90 (15.1)    68 (22.7)    22 (7.4) <0.0001
 200–349  165 (27.7)    87 (29.1)    78 (26.3)
 350–499  169 (28.4)    75 (25.1)    94 (31.6)
 ≥500  161 (27.0)    59 (19.7)  102 (34.3)
 Missing    11 (1.8)    10 (3.3)      1 (0.3)
Antiretroviral drug regimen at time of conceptionb
 Nucleoside reverse transcriptase inhibitor
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Characteristic
Overall
[N = 596 (%)]
South Africa
[N = 299 (%)]
Zambia
[N = 297 (%)] P value
  Abacavir (ABC)      9 (1.5)      1 (0.3)      8 (2.7)   0.020*
  Didanosine (ddI)      2 (0.3)      2 (0.7)      0 (0)   0.499*
  Emtricitabine (FTC)    87 (14.6)      0 (0)    87 (29.3) <0.0001
  Lamivudine (3TC)  505 (84.7)  295 (98.7)  210 (70.7) <0.0001
  Stavudine (d4T)  257 (43.1)  167 (55.9)    90 (30.3) <0.0001
  Tenofovir (TDF)  205 (34.4)    74 (24.7)  131 (44.1) <0.0001
  Zidovudine (ZDV)  128 (21.5)    59 (19.7)    69 (23.2)   0.298
 Non-nucleoside reverse transcriptase inhibitor
  Efavirenz (EFV)  233 (39.1)  157 (52.5)    76 (25.6) <0.0001
  Nevirapine (NVP)  332 (55.7)  117 (39.1)  215 (72.4) <0.0001
 Protease inhibitor
  Indinavir (IDV)      2 (0.3)      2 (0.7)      0 (0)   0.499*
  Lopinavir/ritonavir (LPV/r)    25 (4.2)    20 (6.7)      5 (1.7) <0.003*
  Saquinavir (SQV)      3 (0.5)      3 (1.0)      0 (0)   0.249*
Maternal Events and Pregnancy Outcomes Study, 2010–2012 (N = 596). IQR, interquartile range.
a
In Zambia most women view their main partner as their husband; 254 women considered themselves married, while seven responded as 
cohabiting. In South Africa, no participants reported cohabiting as their marital status.
b
Time of conception refers to 2 weeks after last menstrual period per verbal report, assuming a 28-day menstrual cycle.
*
P value is for Fisher’s exact test (others are Chi-square).
**
P value is for Wilcoxon’s test.
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Table 2
Pregnancy outcomes for all fetuses and viable pregnancies in a cohort of HIV-infected women on combination 
antiretroviral therapy at the time of conception by country.
Outcomes
Overall
[N = 600 (%)]
South Africa
[N = 304 (%)]
Zambia
[N = 296 (%)] P value
Pregnancy outcome
 Live birth, term   427 (71.2)   234 (77.0)   193 (65.2)   0.010
 Live birth, preterm   144 (24.0)     56 (18.4)     88 (29.7)
 Stillbirth, term       3 (0.5)       2 (0.7)       1 (0.3)
 Stillbirth, preterm       9 (1.5)       5 (1.6)       4 (1.4)
 Abortiona     16 (2.7)       6 (2.0)     10 (3.4)
 Ectopic pregnancy       1 (0.2)       1 (0.3)       0 (0)
Gestational age at delivery
 <28 weeks gestation     19 (3.2)       6 (2.0)     13 (4.4) <0.0001
 28–33 weeks gestation     42 (7.0)       6 (2.0)     36 (12.2)
 34–36 weeks gestation   107 (17.8)     54 (17.8)     53 (17.9)
 37–41 weeks gestation   403 (67.2)   234 (77.0)   169 (57.1)
 ≥42 weeks gestation     26 (4.3)       1 (0.3)     25 (8.5)
 Missing specific gestational age       3 (0.5)       3 (1.0)       0 (0)
Characteristics of viable pregnancy outcomesb Overall [N = 583 (%)] South Africa [N = 297 
(%)]
Zambia [N = 286 (%)]   P value
Number of fetuses
 Singleton   559 (95.9)   285 (96.0)   274 (95.8)   0.925
 Of a set of twins     24 (4.1)     12 (4.0)     12 (4.2)
Gestational age at delivery, median weeks (IQR)     38 (36, 40)     38 (37, 39)     38 (36, 40)   0.552**
Sex of infant
 Male   301 (51.6)   167 (56.2)   134 (46.9)   0.023*
 Female   281 (48.2)   129 (43.4)   152 (53.1)
 Not determined       1 (0.2)       1 (0.3)       0 (0)
Birth weight, median grams (%) 2960 (2600, 3240) 2995 (2655, 3265) 2900 (2500, 3200)   0.106**
 <500       1 (0.2)       1 (0.3)       0 (0)   0.866
 500–1499     10 (1.7)       5 (1.7)       5 (1.7)
 1500–2499     88 (15.1)     41 (13.8)     47 (16.4)
 2500–3999   466 (79.9)   240 (80.8)   226 (79.0)
 ≥4000     16 (2.7)       9 (3.0)       7 (2.4)
 Missing       2 (0.3)       1 (0.3)       1 (0.3)
Length of newborn at delivery, median cm (IQR)     49 (47,51)     50 (48, 51)     48 (45, 50) <0.0001**
 Missing   102 (17.5)       4 (1.3)     98 (34.3)
Characteristics of viable pregnancy outcomes Overall [N = 583 (%)] South Africa [N = 297 
(%)]
Zambia [N = 286 (%)]   P value
Mode of delivery
 Vaginal delivery   509 (87.3)   243 (81.8)   266 (93.0) <0.0001
 Cesarean delivery (total)     74 (12.7)     54 (18.2)     20 (7.0)
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Outcomes
Overall
[N = 600 (%)]
South Africa
[N = 304 (%)]
Zambia
[N = 296 (%)] P value
  Nonelective cesarean delivery     41 (55.4)     28 (51.9)     13 (65.0)   0.022*
  Elective cesarean delivery     31 (41.9)     26 (48.1)       5 (25.0)
  Unknown type of cesarean delivery       2 (2.7)       0 (0)       2 (10.0)
Congenital anomaly at delivery     36 (6.2)     20 (6.4)     16 (5.6)   0.545
 Infant with major congenital anomaly     13 (36.1)     11 (55.0)       2 (12.5)
 Infant with minor congenital anomaly     23 (63.9)       9 (45.0)     14 (87.5)
Neonatal deathc
 Term       3 (0.5)       0 (0)       3 (1.0)   0.079*
 Preterm       5 (0.9)       1 (0.3)       4 (1.4)
Maternal Events and Pregnancy Outcomes Study, 2010–2012 (N = 600). IQR, interquartile range.
a
Abortion is defined as estimated gestational age (EGA) less than 28=weeks’ gestation and birth weight below 1000 g. Using the alternate WHO 
definition of EGA less than 22 weeks’ gestation and birth weight below 500 g, South Africa has eight preterm stillbirths and three abortions, and 
Zambia seven preterm stillbirths and seven abortions.
b
Viable pregnancies are defined as EGA at least 28 weeks’ gestation or birth weight at least 1000 g.
c
Percentages are based on live births.
*
P value is for Fisher’s exact test (others are chi-square).
**
P value is for Wilcoxon’s test.
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Table 3
Indications for nonelective cesarean delivery in a cohort of HIV-infected women on combination antiretroviral 
therapy at the time of conception by country.
Indication for cesarean delivery Overall [N = 41 (%)] South Africa [N = 28 (%)] Zambia [N = 13 (%)] P value*
Antepartum hemorrhage 1 (2.4) 1 (3.6) 0 (0) 0.0659
Fetal distress 23 (56.1) 19 (67.9) 4 (30.8)
Malpresentation 1 (2.4) 1 (3.6) 0 (0)
Poor progress of labor   6 (14.6)   3 (10.7) 3 (23.1)
Placenta previa 4 (9.8) 1 (3.6) 3 (23.1)
Severe preeclampsia remote from delivery   5 (12.2) 2 (7.1) 3 (23.1)
Other 1 (2.4) 1 (3.6) 0 (0)
Maternal Events and Pregnancy Outcomes Study, 2010–2012 (N = 41).
*
P value is for Fisher’s exact test.
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